Nutrien Ltd. (TSX:NTR) shares have climbed over 31% in the past year, prompting investors to question if the agricultural giant still presents a buying opportunity. A deep dive into valuation metrics suggests the stock may be fairly priced, but diverging narratives on future growth leave room for debate.
European Commission Vice President Teresa Ribera voices profound shock at the fatal shootings of two protesters in Minneapolis, contrasting with the EU's official cautious stance. Her remarks come as transatlantic tensions simmer over U.S. immigration policies and recent geopolitical threats.
The head of the European Stability Mechanism has told Reuters the bloc's 430-billion-euro emergency fund could be repurposed to provide defense loans to member states, signaling a strategic shift as Europe seeks to bolster its military autonomy.
A New York federal judge has dismissed murder and weapons charges against Luigi Mangione, the man accused of killing UnitedHealthcare's CEO. The ruling deals a significant setback to federal prosecutors and removes the possibility of a death penalty in the high-profile case.
Saks Global moves to close over 60 Off 5th locations as part of Chapter 11 proceedings, signaling a strategic retreat from the competitive off-price segment to focus on core luxury brands.
President Donald Trump's nomination of Kevin Warsh to lead the Federal Reserve sets the stage for a potential pivot in U.S. monetary policy, placing a seasoned yet controversial figure with deep Wall Street ties at the helm.
Exclusive footage and soldier testimonies reveal a disturbing pattern within Russian ranks: wounded amputees, including former prisoners, are being ordered back into combat as casualties mount and manpower dwindles.
In a significant diplomatic gesture, China has agreed to remove travel restrictions on a group of sanctioned British lawmakers, Prime Minister Keir Starmer revealed following talks with President Xi Jinping. The move comes during the first UK leader's visit to China in eight years, aimed at thawing bilateral relations.
Denmark's government announced a bold legislative package aimed at expanding deportations and tightening immigration controls, setting the stage for a potential clash with the European Court of Human Rights.
Secretary-General Antonio Guterres warns in a confidential letter that the United Nations faces a severe cash crunch, driven by unpaid dues and restrictive budget rules, threatening its operational viability by mid-year.
Brazilian President Luiz Inácio Lula da Silva was released from a São Paulo hospital Friday following a planned cataract procedure on his left eye, with his office confirming a swift return to official duties next week.
With the specter of U.S. military action looming, Iran is engaging in a frantic diplomatic push with regional powers like Turkey, while global capitals scramble to prevent a full-scale war. Despite the outreach, analysts warn the window for de-escalation is narrowing.
Bank of America has increased its price target for industrial packaging firm Greif (GEF) by $1 to $75, while reiterating a Neutral rating. The adjustment follows the bank's broader reassessment of the packaging sector after recent quarterly earnings calls.
Analysts at Truist reaffirm their Buy rating on DLocal (DLO), raising their price target to $17 ahead of the fintech firm's Q4 2025 earnings. While expecting solid results, they flag challenging year-over-year volume comparisons that may cap upside surprises.
Rosenblatt Securities initiates coverage on Credo Technology with a Neutral rating and a $170 price target, highlighting its strong position in high-speed connectivity for AI infrastructure while flagging competitive pressures. The note follows a more bullish target hike from Barclays earlier in the month.
Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
B.Riley initiates coverage on BrightSpire Capital (BRSP) with a Buy rating, highlighting its robust cash position and improved credit quality as key drivers for future loan originations, while its stock trades at a discount to book value.
ARMOUR Residential REIT (ARR) received a bullish upgrade from Jones Trading, which moved the stock to Buy with a $20.50 target, citing a discounted valuation and expected book value growth compared to agency mortgage REIT rivals.
Analysts at BTIG have upgraded mortgage REIT Annaly Capital Management (NLY) from 'Neutral' to 'Buy', with a $25 price target, arguing the stock is positioned to benefit from dividend stability and potential spread movements in a turbulent interest rate landscape.
